Skip to main content

Arcus Biosciences, Inc.

corporate_fare Company Profile

Arcus Biosciences, Inc.

RCUS·NYSE·Life Sciences·CIK 0001724521

We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications. Our next wave of clinical-stage molecules are expected to come from our inflammation and autoimmune disease programs. We leverage our internal small-molecule discovery capabilities to create, develop, and commercialize therapies. Our oncology programs include Casdatifan, an oral, small-molecule inhibitor of HIF-2α. HIF-2α is a protein involved in sensing oxygen availability in multiple organs. In certain tumors, particularly clear cell renal cell carcinoma ("ccRCC"), HIF-2α activity is dysregulated due to genetic abnormalities, leading to pseudohypoxia and an increase in HIF-2α-mediated expression of proteins involved in cancer cell proliferation, survival, treatment resistance, and angiogenesis. We designed casdatifan to have superior pharmacokinetic and pharmacodynamic properties relative to belzutifan, with the goal of achieving greater efficacy in ccRCC patients. In our Phase 1/1b ARC-20 study, which evaluated casdatifan monotherapy in approximately 120 late-line ccRCC patients, casdatifan achieved improvement on every efficacy measure, including rate of primary progressive disease, overall response rate ("ORR"), and progression-free survival ("PFS"), relative to data reported for belzutifan in a similar patient population. Taiho holds exclusive licenses for casdatifan in Japan and certain other Asian countries, excluding China. Gilead and Arcus co-develop globally and share co-promotion rights in the U.S. for domvanalimab and quemliclustat. Gilead holds commercialization rights outside of the U.S. subject to Taiho's rights.

Arcus Biosciences, Inc. (NYSE:RCUS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for RCUS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for RCUS spans 8-K, 424B5, 10-Q, DEF 14A.

Recent high-impact activity:

  • Arcus Q3 Revenue Falls to $9M; $288M Raise Extends Cash Runway Into 2029
  • Arcus Posts $9M Q3 Revenue, $694M Cash and Sets Multiple Casdatifan Milestones for Q4
  • Arcus Prices $250M Stock Offering at $17.50, a Discount to $18.03
  • Arcus Files Preliminary Prospectus for Underwritten Common Stock Offering
  • Arcus Launches Underwritten Stock Offering Days After Strong Casdatifan Data

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$247M
Net Income
-$353M
Diluted EPS
-$3.29
Op. Cash Flow
-$482M
Free Cash Flow
-$484M
Operating Income
-$386M
Cash & Equivalents
$222M
Total Debt
$99M
Debt / Equity
0.16×
Net Margin
-142.9%
Shares Outstanding
125.3M sh
Source: 10-K · filed 2026-02-25 · accession 0001724521-26-000009

Short Interest & Short Volume

3.56 days to cover

FINRA reported short interest of 13,177,876 shares in RCUS as of the October 30, 2026 settlement, a 6.6% increase from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 43.2% of RCUS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)13,177,876 shares as of October 30, 2026
Change vs prior period▲ 6.6%
Days to cover3.56 at avg daily volume of 3,698,796
Daily short volume (FINRA facilities)43.2% of 617,293 shares on November 20, 2026
5-day average short volume42.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for RCUS, detected from its recent SEC filings · based on capital-structure filings through 2026-10-22.

1 recent capital raise

Offering Terms Confirmed · Net Proceeds and Use

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$15.5 -0.77% today
52-week range · as of 2026-11-04 $15.5 – $31.73
Market cap
$2.25B
Volume
1.7M (0.7× avg)
3-mo avg 2.2M
Live data · 2026-11-21 07:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RCUS - Latest Insights

RCUS
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.31
Real-time Price: $15.50 info
Change: -$3.81 (-20%) info
Market Cap: $2.249B info
RCUS
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.31
Real-time Price: $15.50 info
Change: -$3.81 (-20%) info
Market Cap: $2.249B info
RCUS
Oct 21, 2026, 10:53 PM EDT
Source: BusinessWire
Importance Score:
7
Updated Oct 23, 4:31 PM ET — The offering closed on October 23, 2026, with the underwriters' option fully exercised, bringing total shares sold to 16,428,572 and net pr…
Price at Filing: $18.03
Real-time Price: $15.50 info
Change: -$2.53 (-14%) info
Market Cap: $2.249B info
RCUS
Oct 21, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $18.75
Real-time Price: $15.50 info
Change: -$3.25 (-17%) info
Market Cap: $2.249B info
RCUS
Oct 21, 2026, 4:22 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.01
Real-time Price: $15.50 info
Change: -$3.51 (-18%) info
Market Cap: $2.249B info
RCUS
Oct 20, 2026, 12:16 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $24.00
Real-time Price: $15.50 info
Change: -$8.50 (-35%) info
Market Cap: $2.249B info
RCUS
Oct 20, 2026, 8:33 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.58
Real-time Price: $15.50 info
Change: -$7.08 (-31%) info
Market Cap: $2.249B info
RCUS
Aug 05, 2026, 4:47 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $28.04
Real-time Price: $15.50 info
Change: -$12.54 (-45%) info
Market Cap: $2.249B info
RCUS
Jul 22, 2026, 5:39 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $29.97
Real-time Price: $15.50 info
Change: -$14.47 (-48%) info
Market Cap: $2.249B info
RCUS
Jul 22, 2026, 4:30 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $30.05
Real-time Price: $15.50 info
Change: -$14.55 (-48%) info
Market Cap: $2.249B info
RCUS
May 05, 2026, 4:31 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $26.06
Real-time Price: $15.50 info
Change: -$10.56 (-41%) info
Market Cap: $2.249B info
RCUS
May 05, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $25.40
Real-time Price: $15.50 info
Change: -$9.90 (-39%) info
Market Cap: $2.249B info
RCUS
Apr 21, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $24.45
Real-time Price: $15.50 info
Change: -$8.95 (-37%) info
Market Cap: $2.249B info
RCUS
Apr 20, 2026, 8:02 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $23.30
Real-time Price: $15.50 info
Change: -$7.80 (-33%) info
Market Cap: $2.249B info
RCUS
Apr 20, 2026, 7:56 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $24.25
Real-time Price: $15.50 info
Change: -$8.75 (-36%) info
Market Cap: $2.249B info
RCUS
Mar 23, 2026, 7:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.64
Real-time Price: $15.50 info
Change: -$6.14 (-28%) info
Market Cap: $2.249B info
RCUS
Feb 25, 2026, 4:39 PM EST
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $20.27
Real-time Price: $15.50 info
Change: -$4.77 (-24%) info
Market Cap: $2.249B info
RCUS
Feb 25, 2026, 4:11 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $20.27
Real-time Price: $15.50 info
Change: -$4.77 (-24%) info
Market Cap: $2.249B info
RCUS
Feb 25, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.27
Real-time Price: $15.50 info
Change: -$4.77 (-24%) info
Market Cap: $2.249B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets